Xenetic Biosciences, Inc. (NASDAQ:XBIO) Sees Large Decrease in Short Interest

Xenetic Biosciences, Inc. (NASDAQ:XBIO) was the target of a large drop in short interest in August. As of August 31st, there was short interest totaling 20,320 shares, a drop of 55.0% from the August 15th total of 45,169 shares. Currently, 1.0% of the shares of the stock are sold short. Based on an average daily volume of 31,148 shares, the days-to-cover ratio is currently 0.7 days.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has a consensus rating of “Sell”.

Xenetic Biosciences Trading Down 2.5%

Shares of Xenetic Biosciences stock traded down $0.11 during trading on Tuesday, reaching $4.22. The company’s stock had a trading volume of 4,997 shares, compared to its average volume of 28,158. The stock has a 50-day moving average price of $3.32 and a two-hundred day moving average price of $3.10. The stock has a market capitalization of $9.67 million, a P/E ratio of -3.64 and a beta of 2.23. Xenetic Biosciences has a one year low of $1.90 and a one year high of $13.93.

Xenetic Biosciences (NASDAQ:XBIO) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter. Xenetic Biosciences had a negative net margin of 75.90% and a negative return on equity of 40.62%. The company had revenue of $0.66 million during the quarter.

About Xenetic Biosciences

Xenetic Biosciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of enhanced protein and peptide therapeutics for oncology, immunology and rare diseases. The company leverages its proprietary platforms to extend the half-life, improve the stability and optimize the delivery of biopharmaceuticals. Xenetic’s pipeline includes novel candidates designed to address unmet medical needs in solid tumors and inherited disorders.

At the heart of Xenetic’s technology portfolio are two complementary platforms: PolyXen, which employs a unique polysialylation process to prolong drug circulation and reduce immunogenicity, and Alphabody, a next-generation antibody-mimetic framework engineered for high-affinity binding to challenging targets.